Cite
HARVARD Citation
Chanchlani, N. et al. (2022). Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study. Alimentary pharmacology & therapeutics. 56 (8), pp. 1250-1263. [Online].